Pharmacokinetics considerations for gout treatments.

about

Comorbidity Burden in Trial-Aligned Patients with Established Gout in Germany, UK, US, and France: a Retrospective Analysis.Update on colchicine, 2017.

P2860

Q37080656-7D26FA3A-C36C-42CA-A99F-C02D4635ACDB Q47177948-28C59A25-A828-43BE-B86A-1F18DC712409

P2860

Pharmacokinetics considerations for gout treatments.

Item

http://www.wikidata.org/entity/Q38210284

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Pharmacokinetics considerations for gout treatments.

@en

type

Item

label

Pharmacokinetics considerations for gout treatments.

@en

prefLabel

Pharmacokinetics considerations for gout treatments.

@en

P1476

Pharmacokinetics considerations for gout treatments.

@en

P2093

Aline Frazier

http://www.w3.org/2001/XMLSchema#string

Pascal Richette

http://www.w3.org/2001/XMLSchema#string

Thomas Bardin

http://www.w3.org/2001/XMLSchema#string

P2860

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition

Gout-associated uric acid crystals activate the NALP3 inflammasome

Urate-lowering therapy for gout: focus on febuxostat

Relation between adverse events associated with allopurinol and renal function in patients with gout

Colchicine for the treatment of gout.

Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.

P304

949-957

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425255.2014.915027

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Thomas Bardin

Pascal Richette

Aline Frazier

P577

2014-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262190205

http://www.w3.org/2001/XMLSchema#string

P698

24809930

http://www.w3.org/2001/XMLSchema#string

Pharmacokinetics considerations for gout treatments.

about

P2860

P2860

Pharmacokinetics considerations for gout treatments.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698